The Letter sent to JBMR
To the Editor of JBMR
We would like to comment on the recent paper by Feldstein et al. on atypical fractures of the femur (1). These fractures were first reported by orthopedic surgeons who were astounded to see typical fatigue type fractures in a non-athletic elderly population. The fracture pattern, also typical for fatigue in many other materials, has been known for over a century, and when this pattern appeared in elderly women, the possible association between material fatigue and bisphosphonate use was conspicuous. Since then, the field has become confused by the introduction of the term "atypical" fracture, which was first used in epidemiologic studies meaning a subtrochanteric location. The new term was then redefined by the ASBMR task force, which introduced criteria for atypical fracture that somewhat vaguely describe a fatigue-type fracture (2). The main feature of this subtype of femoral shaft and subtrochanteric fractures, which struck those who first observed them, is that the fracture line on the lateral side is straight and virtually perpendicular to the cortex.
When this feature is included in the definition, the association between atypical fractures and bisphosphonate use is strong. A Swedish nation-wide, not industry-funded study, in which radiographs from 97% of all shaft or subtrochanteric fractures were reviewed, found a relative risk of 47 for atypical fractures with use of bisphosphonates identified from a complete prescription register. On average, the increase in absolute risk was 5 per 10,000 patient years ( Moreover, there is a suggestion about glucocorticoids as a risk factor of atypical fractures in the abstract, whereas in fact a smaller proportion of the atypical fracture patients had been taking these drugs. If the authors had succeeded in identifying cases with the typical fatigue fracture pattern, an increased prevalence of glucocorticoid use ought to be expected since prolonged glucocorticoid treatment is a common indication for bisphosphonate use. Only bisphosphonates, and no other risk related drugs, were associated with atypical fractures in Schilcher's study.
Feldstein et al. finish their abstract claiming that there is a multitude of associated risk factors for atypical fractures. This statement is not supported by their data. Because of methodological shortcomings, especially regarding fracture classification, they were unable to show the strong relation between bisphosphonate use and atypical (fatigue-type) fractures, which was found in the so far only study covering an entire nation with radiographic adjudication. In fact, the association between bisphosphonate use and these fractures (3) was stronger than the one between tobacco smoking and lung cancer (4), a relation doubted for a long time by some researchers.
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